Tema Oncology ETF Rating $25.78 +0.70 (+2.79%) As of 03:32 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOwnershipRatingsShort InterestTrendsBuy This Stock Tema Oncology ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.CANC Aggregate RatingModerate Buy 2.81Holdings in CANC have an aggregate rating of Moderate Buy based on 570 analyst ratings issued in the past year covering 45 companies (87.5% of the portfolio).CANC Aggregate Price Target$25.78High Prediction$25.78Average Prediction$25.78Low Prediction$25.78Holdings in CANC have an aggregate price target of $25.78 and a range of $25.78 to $25.78 covering 45 companies (87.5% of the portfolio).CANC Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy19 Buy rating(s)Moderate Buy20 Moderate Buy rating(s)Hold6 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Tema Oncology ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 45 CANC Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings5.26%RHHBYRoche$40.87+1.9%N/A2.5775.12%LLYEli Lilly and Company$787.00+1.2%4.98 of 5 stars2.75$1,011.61 28.5%20Trending NewsOptions Volume4.81%RVMDRevolution Medicines$38.52+5.7%4.5538 of 5 stars3.00$68.00 76.5%11News CoveragePositive News4.57%BBIOBridgeBio Pharma$45.98+6.5%4.6844 of 5 stars3.00$58.93 28.2%14Analyst UpgradeGap Up4.05%EXELExelixis$44.07+1.3%4.7034 of 5 stars2.48$44.11 0.1%21Positive NewsAnalyst ForecastOptions Volume3.75%MRUSMerus$54.51+4.2%2.0831 of 5 stars3.14$84.64 55.3%14News CoveragePositive News3.65%GMABGenmab A/S$21.58+1.6%4.0603 of 5 stars2.67$37.80 75.2%12News CoveragePositive NewsAnalyst Forecast3.52%BMYBristol Myers Squibb$47.68+1.4%4.9286 of 5 stars2.32$58.00 21.6%22Positive News3.51%NUVLNuvalent$81.50+3.5%3.7822 of 5 stars3.17$119.60 46.7%123.45%AMGNAmgen$296.52-0.2%4.5247 of 5 stars2.35$307.82 3.8%23Positive News3.32%SMMTSummit Therapeutics$24.74+7.6%2.4762 of 5 stars2.79$34.67 40.1%143.09%ACLXArcellx$69.00+3.7%2.3156 of 5 stars3.07$111.23 61.2%15Positive News2.87%ZLABZai Lab$35.66+2.1%3.2666 of 5 stars2.80$54.28 52.2%5Gap Up2.80%LEGNLegend Biotech$39.46+5.3%3.0481 of 5 stars2.91$72.60 84.0%11Analyst Forecast2.60%MRKMerck & Co., Inc.$83.74+2.9%4.9985 of 5 stars2.43$109.19 30.4%21Trending News2.59%ONCBeOne Medicines$255.69+4.6%3.3579 of 5 stars3.00$320.67 25.4%62.10%IDYAIDEAYA Biosciences$22.97+7.1%3.4092 of 5 stars2.92$49.80 116.8%13News CoverageAnalyst Forecast1.88%ABBVAbbVie$190.74+0.5%4.947 of 5 stars2.81$211.29 10.8%27Trending NewsAnalyst Revision1.69%CGONCG Oncology$27.04+4.2%2.3595 of 5 stars3.00$58.67 117.0%111.65%JANXJanux Therapeutics$25.49+4.3%1.5412 of 5 stars3.09$95.25 273.7%111.41%REGNRegeneron Pharmaceuticals$552.58+0.9%4.914 of 5 stars2.80$813.57 47.2%25Analyst Revision1.40%GILDGilead Sciences$113.24+2.0%4.7418 of 5 stars2.77$111.38 -1.6%26Trending News1.39%ARGXargenex$555.19+3.1%4.4066 of 5 stars3.10$728.06 31.1%21Analyst UpgradeHigh Trading Volume1.39%NRIXNurix Therapeutics$13.18+7.9%1.5824 of 5 stars2.83$30.18 129.0%18News CoverageEarnings ReportUpcoming Earnings1.37%IMNMImmunome$8.89+4.0%1.9753 of 5 stars3.00$23.33 162.5%61.20%COGTCogent Biosciences$10.40+6.3%2.5779 of 5 stars2.82$17.60 69.2%11Trending NewsAnalyst ForecastOptions VolumeHigh Trading Volume1.07%SNDXSyndax Pharmaceuticals$9.24+5.6%3.2914 of 5 stars2.90$35.80 287.4%10News Coverage1.00%DAWNDay One Biopharmaceuticals$7.00+5.9%1.7048 of 5 stars3.14$29.00 314.3%71.00%IMCRImmunocore$34.58+3.9%2.5868 of 5 stars2.55$58.89 70.3%11Positive News0.92%ZYMEZymeworks$13.57+4.8%2.1092 of 5 stars2.90$21.00 54.8%100.92%ELVNEnliven Therapeutics$21.58+8.3%2.689 of 5 stars3.00$41.20 90.9%5Insider TradeHigh Trading Volume0.92%HCMHUTCHMED$16.30+2.3%1.68 of 5 stars2.00$19.00 16.6%20.85%AAPGAscentage Pharma Group International$41.87+1.3%N/A3.001News Coverage0.78%GHGuardant Health$51.04+0.4%3.8352 of 5 stars3.00$53.76 5.3%21Gap Up0.76%ARVNArvinas$8.23+2.6%3.226 of 5 stars2.55$20.29 146.5%22News CoverageHigh Trading Volume0.70%RCUSArcus Biosciences$9.31+9.5%2.5618 of 5 stars2.89$21.29 128.6%90.67%ILMNIllumina$97.44-1.8%4.8918 of 5 stars2.45$127.16 30.5%20News CoveragePositive NewsAnalyst Forecast0.54%REPLReplimune Group$10.39+11.2%4.1764 of 5 stars3.13$20.83 100.5%8High Trading Volume0.50%SDGRSchrodinger$21.68+1.2%2.7895 of 5 stars2.75$33.25 53.4%40.48%RLAYRelay Therapeutics$3.81+6.1%2.5453 of 5 stars2.83$17.67 363.7%120.45%CGEMCullinan Therapeutics$7.80+6.1%1.8947 of 5 stars3.00$30.00 284.6%5News Coverage0.39%NUVBNuvation Bio$2.38+16.1%3.4526 of 5 stars3.20$7.17 201.1%5Gap UpHigh Trading Volume0.39%AUTLAutolus Therapeutics$2.47+4.7%2.1435 of 5 stars3.00$9.32 277.3%50.37%ANABAnaptysBio$25.74+6.1%2.287 of 5 stars2.80$42.38 64.6%100.30%CELCCelcuity$13.51+0.8%1.9748 of 5 stars3.17$28.40 110.2%6 This page (NASDAQ:CANC) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tema Oncology ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Tema Oncology ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
